Europe self-injection market is expected to reach USD 17,595.22 million by 2024 from USD 7,133.88 million in 2016, at a CAGR of 11.9% in the forecast period 2017 to 2024.
Based on geography, the Europe self-injection market is segmented into 11 geographical regions, such as,

Germany,
France,
United Kingdom,
Italy,
Spain,
Russia,
Turkey,
Belgium,
Netherlands,
Switzerland and
Rest of Europe.

Europe Self-injection market competition by top players including -
Sanofi is going to dominate the Europe self-injection market following with Novo Nordisk and Sandoz, Becton, Dickinson and Company along with others such as
Mylan N.V.,
Gerresheimer AG,
West Pharmaceutical Services, Inc.,
Ypsomed,
Antares Pharma,

UNILIFE CORPORATION
The Europe self-injection market is segmented on the basis of product type, application, usage pattern, mode of administration, end user, distribution channel and geography.
The Europe self-injection market is segmented into 4 types, namely needle free injectors (NFI), auto injectors, pen injectors, and wearable injectors.

On the basis of applications, the Europe self-injection market is segmented into hormonal disorders, oncology, autoimmune diseases, orphan diseases, and others. In 2017, 48.7% market share for hormonal disorders applications segment is expected to dominate the market

On the basis of usage pattern the Europe self-injection market is segmented into curative care, immunization.
Based on mode of administration the market is segmented into circulatory, skin, organs and central nervous system.
On the basis of end user the Europe self-injection market is segmented into clinics, hospitals, home care settings, research laboratories and, pharma & biotech companies. In 2017 hospitals and clinics segment dominated the market and the trend is expected to remain the same till 2024.
Based on distribution channel, Europe self injection market is segmented into, Pharmacy stores, hospital pharmacy, direct tender and online pharmacy.